Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003468 · ClinicalTrials.gov registry record · Phase 1
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Lawrence Feldman, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 5
- Study locations
NCT03003468: Completed Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Lawrence Feldman, MD.
NCT03003468 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Lawrence Feldman, MD. The registered enrollment target is 35 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03003468, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Lawrence Feldman, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
Primary Outcome
Phase Ib: Maximum tolerated dose (MTD) for subjects receiving Imprime PGG with pembrolizumab without experiencing dose-limiting toxicity(s) (DLT) per Common Terminology Criteria for Adverse Events (CTCAE) v4.
Conditions Studied
Interventions
- DRUG MK-3475
- DRUG Imprime PGG
Study Locations (5)
Illinois
- University of Illinois at Chicago - Chicago
Indiana
- Indiana Univeristy Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa Hospital and Clinics - Iowa City
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Pennsylvania
- Penn State Cancer Institute - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-07-11 |
| Est. Completion | 2022-11-28 |
| Phase | Phase 1 |
What the finished NCT03003468 record still lists
NCT03003468 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which MK-3475 is the first listed.
NCT03003468 lists 5 locations in 5 states (Illinois, Indiana, Iowa).
Frequently Asked Questions
What is clinical trial NCT03003468 about?
NCT03003468 is a clinical study titled "Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017". This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
What is the current status of trial NCT03003468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-07-11. Estimated completion is 2022-11-28.
What conditions does trial NCT03003468 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03003468?
The interventions under investigation include: MK-3475 (DRUG), Imprime PGG (DRUG).
Who is sponsoring clinical trial NCT03003468?
This trial is sponsored by Lawrence Feldman, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03003468 being conducted?
This trial has 5 study locations across Illinois, Indiana, Iowa, New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03003468's enrollment target sits among peer trials
35 381st of 454 higher than 74 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI